FM SUPERNOTES twenty twenty-five FITE EDITION
How to Use the FM SuperNotes
A Pledge of Support: Your Purchase Makes a Difference
An Appeal for Your Support (A Note to Every User)
Types Of Families: Structure
Ordinal Position ( Differences In Behaviors)
COMMUNICABLE DISEASES IN PRIMARY AND SECONDARY CARE one hundred thirty-four
DERMATOLOGIC AND MUSCULOSKELETAL DISORDERS
PREVENTIVE CARE AND WELLNESS two hundred fifty-one
Family Medicine Principles and Family Practice
Basic Concepts On The Family
Types Of Families: Structure
Parenting Styles And Children's Behavior
How to Construct a Family Genogram
APGAR stands for acronyms of:
Four basic situations where the Family APGAR is needed:
Family APGAR is also valuable in the following conditions or situations:
FES (Family Environment Scale)
Clinical Biographies And Life Chart
RULES IN DRAWING THE ECOMAP
Sample Questions - Family Assessment Tools
Answers & Rationale - Family Assessment Tools
Answers & Rationale - Family Systems Theory
Family Dynamics Assessment Using Minuchin's Family Map
Symbols for boundaries are as follows:
The five basic functions performed by all families
Families adapt to change in the environment.
Families communicate with each other.
Imbalances from basic function of families (over-emphasis or under-emphasis)
Sample Questions - First Order and Second Order Changes
Answers and Rationale - First Order and Second Order Changes
Family Illness Trajectory
STAGE ONE Onset of Illness
Stage ONE - ONSET OF ILLNESS
RESPONSIBILITIES OF THE PHYSICIAN
STAGE TWO - REACTION TO DIAGNOSIS-IMPACT PHASE
RESPONSIBILITIES OF THE PHYSICIAN
STAGE THREE. MAJOR THERAPEUTIC EFFORTS
CRITICAL ISSUES IN CHOOSING THERAPEUTIC PLAN
Economic Impact of illness
RESPONSIBILITIES OF THE PHYSICIAN
STAGE FOUR - RECOVERY PHASE- EARLY ADJUSTMENT TO OUTCOMES
RESPONSIBILITIES OF THE PHYSICIAN:
STAGE FIVE. ADJUSTMENT TO THE PERMANENCY OF THE OUTCOME
Sample Questions - Family Illness Trajectory
WHY DO WE STUDY THE FAMILY LIFE CYCLE?
STAGES OF THE FAMILY LIFE CYCLE
Family with Young Children
THE STAGES OF THE FAMILY LIFE CYCLE
Sample Questions - Family Life Cycle
Answers and Rationale - Family Life Cycle
Primary and Secondary Care - Use of the PFC Matrix
Management of asthma exacerbations in primary care (adults, adolescents, children six to eleven years)
Box three point two. Long-term goal of asthma management
Box three point eight. Indications for considering referral for expert advice, where available
Global Strategy for Asthma Management and Prevention twenty twenty-five
Treatment tracks for adults and adolescents
Track one, in which the reliever is low-dose inhaled corticosteroid-formoterol
Track two, in which the reliever is an inhaled corticosteroid-short-acting beta two-agonist or short-acting beta two-agonist
INITIAL ASTHMA TREATMENT FOR ADULTS AND ADOLESCENTS
Step down to find the minimum effective treatment
Difficult-to-treat and severe asthma
Sample Questions - Asthma
Chronic Obstructive Pulmonary Disease
ANTI-INFLAMMATORY THERAPY IN STABLE COPD
Summary of Recommendations CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (twenty twenty-five REPORT)
CHAPTER THREE: PREVENTION AND MANAGEMENT OF COPD
Palliative Care, End of Life and Hospice Care in COPD
Anti-Inflammatory Therapy in Stable COPD
CHAPTER FOUR: MANAGEMENT OF EXACERBATIONS
Fagerstrom Test for Nicotine Dependence
Diagnosis and Classification of Diabetes
Criteria for the diagnosis of diabetes in nonpregnant individuals
PREDIABETES AND TYPE TWO DIABETES
Criteria for screening for diabetes or prediabetes in asymptomatic adults
POST TRANSPLANTATION DIABETES MELLITUS
MONOGENIC DIABETES SYNDROMES
GESTATIONAL DIABETES MELLITUS
Three. Prevention or Delay of Diabetes and Associated Comorbidities:
LIFESTYLE BEHAVIOR CHANGE FOR DIABETES PREVENTION
PHARMACOLOGIC INTERVENTIONS
PREVENTION OF VASCULAR DISEASE AND MORTALITY
PERSON-CENTERED CARE GOALS
PHARMACOLOGIC INTERVENTIONS TO DELAY SYMPTOMATIC TYPE ONE DIABETES
Four. Comprehensive Medical Evaluation and Assessment of Comorbidities
DECISION CYCLE FOR PERSON-CENTERED GLYCEMIC MANAGEMENT IN TYPE TWO DIABETES
Cognitive Impairment/Dementia
Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Screening
Five. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:
Medical nutrition therapy recommendations
IMPORTANCE OF TWENTY-FOUR-HOUR PHYSICAL BEHAVIORS FOR TYPE TWO DIABETES
SUPPORTING POSITIVE HEALTH BEHAVIORS
Disordered Eating Behavior
Cognitive Capacity or Impairment
Six. Glycemic Goals and Hypoglycemia:
Glycemic Assessment by Continuous Glucose Monitoring
HYPOGLYCEMIA ASSESSMENT, PREVENTION, AND TREATMENT
Classification of hypoglycemia
Components of hypoglycemia prevention for individuals at risk for hypoglycemia at initial, follow-up, and annual visits
Seven. Diabetes Technology
Interfering substances for glucose meter readings
Continuous glucose monitoring devices
Insulin Syringes and Pens
Continuous glucose monitoring devices interfering substances
Do-It-Yourself Closed-Loop Systems
Digital Health Technology
Eight. Obesity and Weight Management for the Prevention and Treatment of Type Two Diabetes
NUTRITION, PHYSICAL ACTIVITY, AND BEHAVIORAL THERAPY
Nine. Pharmacological Approaches to Glycemic Treatment
Ten. Cardiovascular Disease and Risk Management
Pharmacologic Interventions
Ongoing Therapy and Monitoring With Lipid Panel
Treatment of Other Lipoprotein Fractions or Targets
Other Combination Therapy
Eleven. Chronic Kidney Disease and Risk Management
Twelve. Retinopathy, Neuropathy and Foot Care
TREATMENT IN SKILLED NURSING FACILITIES AND NURSING HOMES
Fourteen. Children and Adolescents
Physical Activity and Exercise
Glycemic Monitoring, Insulin Delivery, and Goals
Management of Cardiovascular Risk Factors
Microvascular Complications
Prevention and Management of Diabetes Complications Hypertension
Nonalcoholic Fatty Liver Disease
Polycystic Ovary Syndrome
SUBSTANCE USE IN PEDIATRIC DIABETES Tobacco and Electronic Cigarettes
TRANSITION FROM PEDIATRIC TO ADULT CARE
Fifteen. Management of Diabetes in Pregnancy
GLYCEMIC GOALS IN PREGNANCY
MANAGEMENT OF GESTATIONAL DIABETES MELLITUS
MANAGEMENT OF PREEXISTING TYPE ONE DIABETES AND TYPE TWO DIABETES IN PREGNANCY
PREGNANCY AND DRUG CONSIDERATIONS
Sixteen. Diabetes Care in the Hospital:
Diabetes Care Specialists in the Hospital Recommendation
GLYCEMIC GOALS IN HOSPITALIZED ADULTS
Continuous Glucose Monitoring
Sample Questions - Diabetes
Answers and Rationale - Diabetes
Two. Management of Hypertension Among persons with diabetes
Three. Management of Hypertension in Persons with Chronic Kidney Disease
Four. Blood Pressure Management among Persons with Stroke
Algorithm for Blood Pressure Management at the Emergency Room in Acute Stroke Patients
Clinical Question twenty-one. What blood pressure threshold is used to define hypertension in pregnancy?
When do we treat hypertension during pregnancy?
What are the pharmacologic treatment options in the OPD management of hypertension in pregnancy?
How is hypertension managed during the immediate postpartum and breastfeeding periods?
Six. Blood Pressure Management in the Pediatric Population
Blood Pressure Stages in Filipino Pediatric Population
What are the BP targets for prevention of target organ complications?
What are the preferred medications for children?
What is the recommended technique and BP device for accurate BP measurement in pediatric patients? Statements
Treatment Algorithm for Hypertension in the Pediatric Population
Family-directed Non-pharmacologic Interventions.
Sample Questions - Hypertension
Screening and treatment algorithm for the management of dyslipidemia
Familial Hypercholesterolemia
Dyslipidemia in the Pediatric Population
Risk factors for cardiovascular disease in the pediatric population
Statin treatment intensity
Algorithm for Statin-induced Myopathy
Use of Apolipoprotein B-one hundred
Cholesterol targets for different patient groups
Diagnosis and management of clinical and preclinical obesity
Sample Questions - Clinical Obesity
Ischemic Heart Disease and Coronary Artery Disease
Diagnosis and Management of Patients with Non-ST Elevation Acute Coronary Syndrome
Diagnosis and Management of Patients with ST Segment Elevation Myocardial Infarction
Answers and Rationale - IHD/CAD
Recommendation for the treatment of patients with symptomatic heart failure with mildly reduced ejection fraction
Management of patients with heart failure with mildly reduced ejection fraction.
Recommendation for the treatment of patients with symptomatic heart failure with preserved ejection fraction
Management of patients with heart failure with preserved ejection fraction.
Recommendations for the management of iron deficiency in patients with heart failure.
DEFINITION OF HEART FAILURE
Classification of Heart Failure by Left Ventricular Ejection Fraction
Diagnostic Algorithm for Classification of Heart Failure According to Left Ventricular Ejection Fraction
Other Potential Nonischemic Causes of Heart Failure
Clinical Assessment: History and Physical Examination
Initial Laboratory and Electrocardiogram
Use of Biomarkers for Prevention, Initial Diagnosis, and Risk Stratification
Examples of Factors Implicating Possible Genetic Cardiomyopathy
Evaluation With Cardiac Imaging
Wearables and Remote Monitoring (Including Telemonitoring and Device Monitoring)
Exercise and Functional Capacity Testing
Initial and Serial Evaluation: Clinical Assessment: HF Risk Scoring
STAGE A (PATIENTS AT RISK FOR HF)
Recommendations (Class one and two a) for Patients at Risk of HF (Stage A) and Those With Pre-HF (Stage B).
Other ACC/AHA Clinical Practice Guidelines Addressing Patients With Stage B HF
Nonpharmacological Interventions
Treatment of HFrEF Stages C and D.
Dietary Sodium Restriction
Potential Barriers to Effective HF Self-Care and Example Interventions
Diuretics and Decongestion Strategies in Patients With HF
Commonly Used Oral Diuretics in Treatment of Congestion for Chronic HF
Renin-Angiotensin System Inhibition With ACEi or ARB or ARNi
Mineralocorticoid Receptor Antagonists (MRAs)
Sodium-Glucose Cotransporter two Inhibitors
Hydralazine and Isosorbide Dinitrate
Drugs of Unproven Value or That May Worsen HF
Selected Prescription Medications That May Cause or Exacerbate HF
Drugs Commonly Used for HFrEF (Stage C HF)
Management of Stage C HF: Ivabradine
Pharmacological Treatment for Stage C HFrEF: Digoxin
Pharmacological Treatment for Stage C HFrEF: Soluble Guanylyl Cyclase Stimulators
Device and Interventional Therapies for HFrEF
Algorithm for CRT Indications in Patients With Cardiomyopathy or HFrEF.
Other Implantable Electrical Interventions
Revascularization for CAD